Novartis announced that the CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients treated with canakinumab (ACZ885) combined with pembrolizumab plus platinum-based doublet chemotherapy, compared to patients receiving placebo in combination with pembrolizumab plus platinum-based doublet chemotherapy.
- Read more about CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/canopy-1-phase-iii-study-did-not-demonstrate-the-statistically-significant-primary-endpoints
No comments:
Post a Comment